27 February 2018

GP18: Call for abstracts – Closing soon

Abstract submissions for GP18 close Sunday 4 March 2018 (AEST). Don’t miss the opportunity to present to your peers at the most popular event for GPs in 2018.

The GP18 Scientific Committee is calling for 15-minute, 30-minute and one-hour oral and poster presentations.

GP18 will take place on the Gold Coast from 11–13 October.

Visit the GP18 website for more information.

Introduction to point-of-care ultrasound for GPs

GPs and registrars with an interest in ultrasound can learn more about this effective diagnostic tool at one of six workshops held throughout Australia.

RACGP Rural is offering a series of Introduction to point-of-care ultrasound for GPs workshops across the country in the coming weeks. Each workshop will be available for members in Darwin, Bunbury, Sydney, Brisbane, Adelaide and Burnie.

This Active Learning Module provides participants with an opportunity to identify practical applications of ultrasound technology in primary care and to use point-of-care ultrasound devices under the guidance of experts.

Please visit the RACGP Rural events calendar for more information and to register.

Expressions of interest for Australian General Practice Training program

Expressions of interest for residents and interns wishing to apply for the 2019 Australian General Practice Training (AGPT) program are now open.

By submitting an expression of interest with the RACGP, you will receive the latest news and updates prior to applications opening.

Applications for selection into the 2019 AGPT Program open at 10am Monday 26 March 2018 (AEDT) and close at 10am on Monday 30 April 2018 (AEST).

Visit the RACGP’s AGPT webpage to submit an expression of interest or view the comprehensive 2019 AGPT selection guide.

Severe Euglycaemic Ketoacidosis with SGLT2 Inhibitor Use in the Perioperative Period

The Australian Diabetes Society has advised of recent reports where patients with type 2 diabetes are taking sodium-glucose co-transporter-2 inhibitors (SGLT2i) medications developing severe acidosis requiring ICU/HDU admission during the peri-operative period.

SGLT2i are oral medications for the treatment of type 2 diabetes, and include dapagliflozin (Forxiga), empagliflozin (Jardiance), or a combination with metformin (Xigduo, Jardiamet). Severe diabetic ketoacidosis (DKA) can occur where the blood glucose level is < 16 mmol/L. This risk is increased in patients who have been fasting, have very restricted dietary intake, have undergone a surgical procedure, were dehydrated or had active infection.

These agents may also reduce urinary ketone excretion, so urine ketone testing may be unreliable. Ketosis is only detected by blood ketone testing.

SGLT2i be ceased at least three days pre-operatively (two days prior to surgery and the day of surgery) or in other physically stressful situations. This may require an increase in other glucose-lowering drugs during this time.

Visit the Australian Diabetes Society website to view the position statement and the Therapeutic Goods Administration website to view the recommendations for health professionals in general practice.

Media enquiries

Journalists and media outlets seeking comment and information from the RACGP should contact:

John Ronan

Senior Media Advisor